Trovagene launches cancer urine test; Frazier Healthcare amasses $377M fund;

@FierceMedDev: ICYMI yesterday... Report: Blackstone, Bain, other equity firms bid for J&J's Ortho Clinical Diagnostics unit. Article | Follow @FierceMedDev

@MarkHFierce: Myriad's stock dived earlier this week over Dx reimbursement fears driven by what turned out to be a clerical error. Story from FierceDiagnostics | Follow @MarkHFierce

> Precision Spine won expanded 510(k) clearance for a number of additional components of its Reform pedicle screw system to treat spinal deformities. Item

> San Diego's Trovagene ($TROV) has launched a test that can monitor cancer-tied BRAF mutations through urine. More

> Delcath ($DCTH), still reeling from an FDA rejection of its Melblez drug-device combo, received an agency orphan drug designation for the system. Item

> Life sciences venture capital firm Frazier Healthcare has amassed a $377 million fund with an eye on biotech and medical device companies. News

> Surgical devicemaker Synergetics USA said its fourth quarter net income dropped 26% because of weak activity in emerging markets. Story

Biotech News

@FierceBiotech: ICYMI yesterday: What happens to the FDA in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Cancer immunotherapies turn a corner in race to megablockbuster market. Article | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Government shutdown halts NIH research, CDC disease surveillance. Story from FierceBiotech Research | Follow @EmilyMFierce

@DamianFierce: Wall Street is less than thrilled with Stryker's $1.7B deal for MAKO, but CEO says just you wait. Story from FierceMedicalDevices | Follow @DamianFierce

> Fate IPO flop raises fresh concerns about investors' appetite for biotech. News

> VC Frazier Healthcare nails $377M fund with eye on biotech startups. More

Pharma News

@FiercePharma: MS cases grow by 10% in 5 yrs, with most in US, Europe. Drugs access a problem, esp in low-income countries. More | Follow @FiercePharma

@EricPFierce: The success of some drugs shortly after launch suggest stardom. Special report | Follow @EricPFierce

@CarlyHFierce: From today's edition of FierceBiomarkers: Molecular switch could control metastases, aid diagnosis in breast cancer. Article | Follow @CarlyHFierce

> PhRMA sues feds over new rule on orphan-drug discounts. Story

> Judge sweeps aside AstraZeneca shield against Nexium competitor. More

> Shire aims to win skeptical Europe over to ADHD drugs. Article

Biomarkers News

> Report: Biomarkers market to grow 18.5% by 2018. Story

> Medicare's rejection of Alzheimer's test leaves Lilly in the lurch. Article

> Quintiles looks to biomarkers to speed up cancer trials. Report

> Research finds possible biomarker for Parkinson's with mild cognitive impairment. News

Drug Delivery News

@MichaelGFierce: Vaginal polymer ring delivers long-term HIV-preventing drug. Item | Follow @MichaelGFierce

> Hypertension drug could help chemo infiltrate tumors. More

> John Theurer Cancer Center touts two oral lymphoma drug studies. Story

> Oral peptide delivery biz Enteris lands Nordic partnership. Report

> MIT nanoparticles help deliver vaccines to mucosal surfaces. More

> Medtronic lands U.S. approval of early-generation artificial pancreas. Article

Diagnostics News

> Singulex will jump into in vitro diagnostics backed by $55M in debt, equity. Item

> UCLA team develops superfast fluorescent camera with Dx benefit. Story

> MA company debuts Dx device that could dramatically speed up HIV, other tests. Report

> Chronix preclinical study boosts CLIA goal for cell-free DNA cancer test. More

> Myriad reimbursement scare sent stock on roller coaster ride. Article

> Roche, Pacific Biosciences forge clinical Dx deal. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.